Melagatran
CAS: 159776-70-2
Ref. 3D-FM25041
| 1mg | To inquire | ||
| 2mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire |
Product Information
- N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycineH-319/68
- Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-
- Glycine, N-[2-[2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-, [S-(R*,S*)]-
- H-319/68
- N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycine
- N-[(1R)-2-{(2S)-2-[(4-carbamimidoylbenzyl)carbamoyl]azetidin-1-yl}-1-cyclohexyl-2-oxoethyl]glycine
Melagatran is a coumarin derivative that acts as a thrombin receptor antagonist. It has been shown to have anti-thrombotic effects in an experimental model of balloon injury and in a vivo model of arterial thrombosis. Melagatran has been shown to significantly inhibit the progression of atherosclerotic lesions when administered orally, without adverse effects on blood coagulation or liver function. This drug may be useful for the prevention or treatment of cardiovascular disease in patients with hepatic impairment. Melagatran is rapidly converted into melagatran in vivo and has no significant pharmacological activity. The drug can be detected by analytical methods such as high performance liquid chromatography (HPLC).
Chemical properties
Technical inquiry about: 3D-FM25041 Melagatran
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
